73 completed. 73 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 73 | Completed 73 |
| Phase 2 | 3 | Completed 3 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder | Phase 3 | Completed | Dong-A ST Co., Ltd. | 607 | 2022-05-12 | 2024-06-26 |
| To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder JLP-2002 A mg, Placebo - Overactive Bladder | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 210 | 2020-05-21 | 2022-01-28 |
| Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia Vibegron - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 276 | 2019-09-19 | 2024-08-21 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) Vibegron, Placebo - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1105 | 2019-03-26 | 2024-08-07 |
| An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Vibegron, placebos, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 506 | 2018-06-14 | 2021-03-18 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) vibegron, Vibegron placebo, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1530 | 2018-03-26 | 2021-03-04 |
| Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease solifenacin, Pelvic floor muscle exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 3 | Completed | VA Office of Research and Development | 77 | 2018-03-01 | 2024-09-24 |
| Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity GSK1358820, Placebo - Urinary Bladder, Overactive | Phase 3 | Completed | GlaxoSmithKline | 21 | 2016-10-11 | 2021-07-14 |
| Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder GSK1358820, Placebo, Antibiotic therapy - Urinary Bladder, Overactive | Phase 3 | Completed | GlaxoSmithKline | 250 | 2016-08-10 | 2020-11-27 |
| Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. Uritos®, Urotol® - Overactive Bladder | Phase 3 | Completed | R-Pharm | 300 | 2016-07-18 | 2019-05-21 |
| Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. Fesoterodine - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 26 | 2015-10-01 | 2019-07-30 |
| Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan Mirabegron 25mg - Urinary Incontinence, Overactive Bladder Syndrome | Phase 3 | Completed | Buddhist Tzu Chi General Hospital | 168 | 2015-04-28 | 2017-02-23 |
| Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB THVD-201, Placebo(For THVD-201), Detrusitol 2mg tablet - Overactive Bladder | Phase 3 | Completed | SK Chemicals Co., Ltd. | 384 | 2015-01-01 | 2017-01-12 |
| Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children Fesoterodine, Oxybutynin XL - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 62 | 2014-12-01 | 2019-07-30 |
| Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women Darifenacin, Physiotherapy - Overactive Bladder | Phase 3 | Completed | Universidad de Valparaiso | 80 | 2014-05-01 | 2016-05-02 |
| A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin - Urinary Bladder Overactive, Overactive Bladder | Phase 3 | Completed | Astellas Pharma Europe B.V. | 1829 | 2014-03-17 | 2024-10-31 |
| This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate - Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases | Phase 3 | Completed | Astellas Pharma Europe B.V. | 3527 | 2013-11-05 | 2024-10-31 |
| A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg - Urinary Bladder Diseases, Urinary Bladder Overactive | Phase 3 | Completed | Astellas Pharma Europe Ltd. | 2174 | 2013-07-10 | 2024-10-31 |
| Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder Mirabegron - Overactive Bladder, Urinary Incontinence | Phase 3 | Completed | CHU de Quebec-Universite Laval | 35 | 2013-04-01 | 2018-04-24 |
| Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder mirabegron - Overactive Bladder, Urinary Incontinence | Phase 3 | Completed | CHU de Quebec-Universite Laval | 58 | 2013-04-01 | 2018-06-20 |
Showing 20 of 73. Sign in to see all of them.
Urinary Incontinence (23) · Urinary Incontinence, Urge (13) · Urologic Diseases (5) · Lower Urinary Tract Symptoms (4) · Nocturia (4) · Prostatic Hyperplasia (2) · Urinary Bladder Diseases (2) · Male Urogenital Diseases (1) · Multiple Sclerosis (1) · Parkinson Disease (1) · Syndrome (1) · Urinary Bladder, Neurogenic (1)
Female Urogenital Diseases (73) · Female Urogenital Diseases and Pregnancy Complications (73) · Pathological Conditions, Signs and Symptoms (73) · Signs and Symptoms (73) · Urogenital Diseases (73) · Urological Manifestations (73) · Male Urogenital Diseases (72) · Urinary Bladder Diseases (71) · Lower Urinary Tract Symptoms (69) · Urologic Diseases (68) · Urination Disorders (30) · Urinary Incontinence (7) · Nervous System Diseases (3) · Genital Diseases (2) · Genital Diseases, Male (2)
Solifenacin Succinate (18) · Tolterodine Tartrate (16) · mirabegron (14) · Botulinum Toxins, Type A (9) · fesoterodine (8) · Saline Solution (5) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (4) · propiverine (4) · darifenacin (3) · imidafenacin (3) · oxybutynin (3) · Anti-Infective Agents (1) · Behavior Therapy (1) · DA-8010 (1) · Drug Therapy (1)
Astellas Pharma Inc (14) · Allergan (7) · Pfizer (7) · Astellas Pharma Europe B.V. (4) · Urovant Sciences GmbH (4) · APOGEPHA Arzneimittel GmbH (2) · Astellas Pharma Europe Ltd. (2) · CHU de Quebec-Universite Laval (2) · Duramed Research (2) · GlaxoSmithKline (2) · Novartis (2) · Ono Pharmaceutical Co., Ltd. (2) · Stéphane Bolduc (2) · Bayer (1) · Boston Scientific Corporation (1)
United States (40) · Canada (21) · Poland (20) · Belgium (18) · Germany (18) · United Kingdom (17) · Czechia (16) · Russia (15) · Spain (14) · Hungary (13) · Slovakia (13) · South Korea (13) · Ukraine (13) · Italy (12) · Sweden (12)
Alexis Te (1) · Anthony Visco, MD (1) · Benjamin Li, PhD (1) · Cris Constantinescu, MD PhD (1) · Daniela Marschall-Kehrel, MD (1)
PMID 37160401, PMID 24246044, PMID 35881009, PMID 21293089, PMID 24754838, PMID 25288099, PMID 26231052, PMID 37811598, PMID 18502028, PMID 18584946, PMID 18663723, PMID 19143854, PMID 19233423, PMID 19348029, PMID 20121659, PMID 20707767, PMID 20723260, PMID 20829244, PMID 21428726, PMID 21798658, PMID 22008247, PMID 22092152, PMID 22503020, PMID 22965657, PMID 23036134, PMID 23448285, PMID 23608668, PMID 23769122, PMID 23892704, PMID 26516810, PMID 26876327, PMID 26965560, PMID 27564385, PMID 27687820, PMID 28150436, PMID 28916436, PMID 29866467, PMID 31930360, PMID 32239291, PMID 32665528, PMID 33231929, PMID 33332699, PMID 33356445, PMID 33469832, PMID 33620895, PMID 34292493, PMID 34921665, PMID 35685566, PMID 36384907, PMID 37586052
2017 (2), 2018 (2), 2008 (1), R03AG042335 (1), U01HD041249 (1), U10HD041250 (1), U10HD041261 (1), U10HD041267 (1), U10HD054136 (1), U10HD054214 (1), U10HD054215 (1), U10HD054241 (1)